November 2024 in “International Journal of Molecular Sciences” This study developed caffeine-loaded nanoparticles coated with ultradeformable liposomes for better hair follicle delivery, showing non-cytotoxicity and potential to reduce oxidative stress in DHT-damaged cells, suggesting an alternative treatment for androgenetic alopecia.
October 2024 in “International Journal of Pharmaceutics” This study aimed to develop a new transdermal patch for treating androgenetic alopecia using finasteride, combined with chemical permeation enhancers to improve drug delivery through the skin, but results of pharmacokinetics and pharmacodynamics evaluations are not reported.
September 2024 in “Stem Cell Research & Therapy” This study found that extracellular vesicles derived from hyaluronic acid-stimulated induced pluripotent stem cells significantly improved hair growth in a model of androgenetic alopecia in mice by enhancing Wnt/β-catenin signaling and regulating androgen receptor activity, showing comparable results to the commonly used treatment finasteride.
August 2024 in “Journal of Controlled Release” In a study using an AGA mouse model, researchers observed that a novel topical gel combining hybrid extracellular vesicles, gold nanoparticles, and finasteride accelerated hair regrowth and improved hair quality more effectively than conventional minoxidil treatment, presenting a promising option with fewer side effects.
June 2024 in “Journal of medicinal chemistry” This study developed a method for designing peptide-based PROTAC drugs using advanced AI models, successfully identifying peptides that bind to specific receptors and incorporating them into a potential transdermal treatment for androgenetic alopecia.
May 2024 in “Nano letters” This study developed a quercetin-encapsulated and polydopamine-integrated nanosystem that reshapes the perifollicular microenvironment, showing potential for rescuing hair follicle viability and regenerating hair follicles in androgenic alopecia by scavenging reactive oxygen species and promoting angiogenesis.
This study developed a personalized microneedle that delivers finasteride directly to the skin, facilitating a sustained release and potentially reducing side effects associated with oral administration.
April 2024 in “Expert opinion on emerging drugs” In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.
April 2024 in “AAPS PharmSciTech” New microneedle method improves hair regrowth treatment delivery.
March 2024 in “ACS Applied Materials & Interfaces” This study developed a delivery platform using hyaluronic acid-based dissolvable microneedles with nanoliposomes containing kopexil and kopyrrol, which showed improved hair regeneration for treating androgenetic alopecia in vivo at lower dosages compared to minoxidil.
February 2024 in “International Journal of Pharmaceutics” This study found that combining the natural product cedrol with minoxidil can improve the treatment of androgenetic alopecia by reducing the minoxidil dose needed, while a new nanocarrier system enhances drug delivery and effectiveness at hair follicles.
February 2024 in “Drug Delivery and Translational Research” In this study, a newly developed cardamonin-loaded liposomal formulation significantly enhanced hair growth and improved hair follicle performance in mice with androgenic alopecia.
1 citations
,
January 2024 in “Journal of molecular structure” This study developed a new finasteride release system using chitosan-based nanoniosomes, observing that 70% of the drug was released over ten days in vitro, suggesting potential for prostate cancer prevention.
January 2024 in “Advanced Healthcare Materials” In a mouse model of androgenetic alopecia, this study developed a treatment combining a copper-curcumin nanoparticle oleogel with traditional Gua Sha therapy, which augmented hair regeneration more effectively than minoxidil by improving the follicular microenvironment and regulation of inflammatory responses.
December 2023 in “International Journal of Biological Macromolecules” This study found that MCS nanoparticles improved Minoxidil's hair growth effects in an animal model compared to the commercial formulation, but they were less effective than CS nanoparticles despite showing better solubility with minimal side effects.
December 2023 in “European Journal of Medicinal Chemistry” This review highlights potential therapeutic mechanisms of natural products for androgenetic alopecia, suggesting they may modulate signaling pathways and have anti-inflammatory and antioxidant effects.
November 2023 in “International Journal of Pharmaceutics” This study found that a new transdermal drug delivery system using globefish skin collagen peptides and dissolving microneedles effectively promoted hair regrowth in mice with androgenetic alopecia by reducing inflammation and enhancing vascularization.
November 2023 in “International Journal of Pharmaceutics” This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.
November 2023 in “International Journal of Medical Sciences” This review examines the mechanisms of hair follicle development and regeneration, discussing current hair loss treatments and emerging therapies like low-level laser therapy and stem cell therapy, which the authors suggest show promise in managing hair loss.
1 citations
,
July 2023 in “International Journal of Biological Macromolecules” In this study, researchers developed a composite paste system using minoxidil-loaded nanoparticles and valproic acid, enhanced by roller-microneedles, which significantly stimulated hair regeneration and perifollicular vascularization in an androgenetic alopecia mouse model, reducing side effects compared to traditional treatments.
4 citations
,
July 2023 in “Pharmaceutics (Basel)” This study reviews various skin models and methodologies used to assess the follicular penetration of nanoparticle-based drugs, highlighting inconsistencies that complicate comparisons and aims to establish more uniform protocols for clearer study outcomes.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
May 2023 in “Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy” This study developed a synchronized fluorescence spectroscopic approach to quantify finasteride and tadalafil in various forms, achieving high accuracy with %recoveries of about 99.62% and 100.19% respectively, and demonstrated superior environmental friendliness compared to previous methods.
1 citations
,
January 2023 in “Drug Development and Industrial Pharmacy” This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.
1 citations
,
December 2022 in “Journal of Controlled Release” This review summarizes recent research on microneedles for alopecia treatment and hair regrowth, noting their potential to improve drug delivery and patient outcomes, but reports no new clinical results.
1 citations
,
December 2022 in “Bioactive Materials” In this study, researchers developed a nanocomposite microneedle patch containing copper/zinc dual-doped silica nanoparticles, which release substances to promote hair follicle regeneration by targeting various pathophysiological aspects of androgenic alopecia, presenting an effective anti-hair loss treatment strategy.
1 citations
,
November 2022 in “Aaps Pharmscitech” August 2022 in “Journal of Cosmetic Dermatology” This study found that 1% topical cetirizine may be more effective than a placebo in treating androgenetic alopecia but appears less effective than minoxidil for hair density, though potentially longer-lasting; however, more well-designed RCTs are needed to confirm these findings.
14 citations
,
May 2022 in “Asian Journal of Pharmaceutical Sciences” This review article highlights how hair follicle-targeting drug delivery systems enhance therapeutic outcomes and reduce side effects for treating conditions like androgenetic alopecia and acne vulgaris. The authors discuss current formulations and evaluate their performance in both preclinical and clinical settings.
5 citations
,
April 2022 in “Journal of Ethnopharmacology” This review discusses the therapeutic mechanisms of Traditional Chinese Medicine in treating alopecia but reports no new clinical results; the authors emphasize the need for more guided clinical application and research on herbal combinations.
6 citations
,
January 2022 in “Journal of Investigative Dermatology” This study found that androgen receptor signaling is linked to blood vessel regression in the dermal papilla of balding scalp, contributing to hair follicle miniaturization in androgenetic alopecia.
January 2022 in “Drug Delivery” This study investigated a finasteride and oregano oil-loaded nano-cubosome gel formulation, finding it enhanced drug release and skin permeation and demonstrated synergistic antibacterial effects, suggesting potential for treating alopecia areata.
1 citations
,
January 2022 in “BioMed Research International” This study reported that solid lipid nanoparticles of finasteride decorated with chitosan enhanced drug retention in skin layers, suggesting potential application in treating androgenic alopecia and benign prostate hyperplasia with fewer side effects.
December 2021 in “Indian Journal of Dermatology, Venereology and Leprology” In this study, androgenetic alopecia patients exhibited more nailfold capillary abnormalities, suggesting a potential link between microcirculation issues and the condition.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
38 citations
,
July 2021 in “ACS Nano” This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.
23 citations
,
July 2021 in “International Journal of Pharmaceutics” This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.
10 citations
,
February 2021 in “International Journal of Nanomedicine” This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.
January 2021 in “Korean Journal of Chemical Engineering” This study found that preparing Finasteride micro and nanoparticles using a gas-antisolvent method reduced the particle size significantly.
28 citations
,
November 2020 in “Journal of Controlled Release” In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.
13 citations
,
September 2020 in “Dermatologic Therapy” This review discusses the use of microneedling for androgenetic alopecia and finds it promising for enhancing hair density and thickness, especially when combined with other treatments, but notes no standardized protocol exists yet.
6 citations
,
August 2020 in “Journal of Pharmaceutical Innovation” This study found that a lipid nanoemulsion-based gel of finasteride for topical use improved hair growth and was effective against alopecia, with slow skin permeation and increased efficacy compared to a testosterone-treated group.
59 citations
,
March 2020 in “Journal of Biomedical Science” This study explored the complex roles of niche cells in regulating hair follicle stem cells, identifying specific cell functions such as signaling, sensing, and relaying messages, which could provide insights into treating hair loss conditions like androgenetic alopecia and alopecia areata.
14 citations
,
January 2020 in “Biomaterials Science” Created microspheres show potential for safe and effective use in prostate artery embolization.
6 citations
,
March 2019 in “International Journal of Molecular Medicine” This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.
14 citations
,
August 2018 in “Journal of Pharmaceutical and Biomedical Analysis” This study found that finasteride maintained chemical and physical stability in various excipient mixtures, which may guide the development of stable topical delivery systems.
28 citations
,
February 2016 in “International Journal of Nanomedicine” This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.
